Does LORLATINIB Cause Hepatic lesion? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hepatic lesion have been filed in association with LORLATINIB (Lorbrena). This represents 0.1% of all adverse event reports for LORLATINIB.
7
Reports of Hepatic lesion with LORLATINIB
0.1%
of all LORLATINIB reports
0
Deaths
3
Hospitalizations
How Dangerous Is Hepatic lesion From LORLATINIB?
Of the 7 reports, 3 (42.9%) required hospitalization.
Is Hepatic lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LORLATINIB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Neoplasm progression (633)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
What Other Drugs Cause Hepatic lesion?
OCTREOTIDE (296)
EVEROLIMUS (171)
RIBOCICLIB (144)
LETROZOLE (139)
CAPECITABINE (124)
ADALIMUMAB (123)
METHOTREXATE (108)
FULVESTRANT (107)
PALBOCICLIB (104)
CYCLOPHOSPHAMIDE (101)
Which LORLATINIB Alternatives Have Lower Hepatic lesion Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE